Stakeholders Urge Tweaks in Draft Guidance on Pregnant Trial Subjects

Drug Industry Daily
A A
The FDA’s draft guidance on inclusion of pregnant women in clinical trials needs some fine tuning, according to stakeholders, including more clarity on non-adherence to therapies.

To View This Article:

Login

Subscribe To Drug Industry Daily